Topical treatment of cutaneous leishmaniasis.

El‐On, Joseph; Livshin, R; Paz, Ziv; Weinrauch, Louis

doi:10.1136/bmj.291.6504.1280-b

Cited by 32 publications

(19 citation statements)

References 3 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The poor results with PR when combined with urea emphasize the antileishmanial properties of MBCL shown by El-On and Messer 19 and the synergetic anti leishmanial effect of MBCL and PR. 20 Additionally, PR as an antibiotic may reduce secondary infections and promote healing. Only in a recent controlled trial in Ecuador has the combination of PR with urea showed a similar cure rate of CL (70% in 30 patients) as PR-MBCL (78.2% in 23 patients) and meglumine antimonate (88.6% in 35 patients) after 1 year of observation; however, the treatment period was very long: twice a day for at least 12 weeks.…”

Section: Discussionmentioning

confidence: 99%

Randomized, controlled, double-blind trial of topical treatment of cutaneous leishmaniasis with paromomycin plus methylbenzethonium chloride ointment in Guatemala.

Arana¹,

Mendoza²,

Rizzo³

et al. 2001

The American Journal of Tropical Medicine and Hygiene

113

View full text Add to dashboard Cite

Abstract. A double-blind, randomized trial was undertaken in Guatemala to determine the therapeutic efficacy of an ointment for the treatment of cutaneous leishmaniasis that contained 15% paromomycin and 12% methylbenzethonium chloride and that was applied twice a day for 20 days. The treatment group included 35 patients, and the placebo group included 33 patients. The initial clinical response rate (13 weeks after completing the treatment) was 91.4% in the treatment group and 39.4% in the placebo group. The final clinical response rate at the 12-month followup examination was 85.7% (31 of 35) in the treatment group and 39.4% (13 of 33) in the placebo group (P Յ 0.001). In general, the treatment was well tolerated and was never interrupted because of adverse effects. The number of adverse effects reported in the placebo group was lower than in the treatment group (16 events versus 30 events). All adverse effects reported by patients disappeared within 1 week of completing the treatment. Our findings show that the combination of paromomycin with methylbenzethonium chloride for 20 days is a good alternative for antimonial treatments of cutaneous leishmaniasis in Guatemala.

show abstract

Section: Discussionmentioning

confidence: 99%

Randomized, controlled, double-blind trial of topical treatment of cutaneous leishmaniasis with paromomycin plus methylbenzethonium chloride ointment in Guatemala.

Arana¹,

Mendoza²,

Rizzo³

et al. 2001

The American Journal of Tropical Medicine and Hygiene

113

View full text Add to dashboard Cite

show abstract

“…Among them, paromomycin (aminosidine) has shown antileishmanial activity when used alone or in combination with other drugs (7,10,17,18,20). Topical treatments with paromomycin-containing ointments or intramuscular injections of the same antibiotic have been successfully used for a long time against cutaneous or visceral leishmaniasis, respectively (7,23,32,34).…”

mentioning

confidence: 99%

“…The disease may reach an appreciable mortality rate and may adopt several forms in human patients, ranging from cutaneous and mucocutaneous lesions to a severe visceral form affecting various organs (7,10,20).…”

mentioning

confidence: 99%

Differential Effects of Paromomycin on Ribosomes of Leishmania mexicana and Mammalian Cells

Fernández

Malchiodi

Algranati

2011

Antimicrob Agents Chemother

View full text Add to dashboard Cite

Paromomycin, an aminoglycoside antibiotic having low mammalian cell toxicity, is one of the drugs currently used in the chemotherapy of cutaneous and visceral leishmaniasis. In order to understand the mode of action of this antibiotic at the molecular level, we have investigated the effects of paromomycin on protein synthesis in Leishmania and its mammalian hosts. We were able to demonstrate that in vivo protein synthesis in the promastigote stage of the parasite and its proliferation rate are markedly inhibited by paromomycin while being only slightly affected by other aminoglycoside antibiotics, such as streptomycin and neomycin B. Furthermore, both in vitro polypeptide synthesis induced by poly(U) as mRNA and accuracy of translation are significantly decreased by paromomycin in cell-free systems containing ribosomal particles of Leishmania promastigotes. Conversely, when ribosomes from mammalian cells are used instead of the protozoan particles, polyphenylalanine synthesis is only barely reduced by the antibiotic and the translation misreading remains almost unaltered. Surface plasmon resonance analysis of the interaction between paromomycin and protozoan or mammalian cell ribosomal RNAs shows a strong binding of antibiotic to the parasite ribosomal decoding site and practically no interaction with the mammalian cell counterpart. Our results indicating differential effects of paromomycin on the translation processes of the Leishmania parasite and its mammalian hosts can explain the therapeutic efficiency of this antibiotic as an antileishmaniasis agent.

show abstract

“…Paromomycin %15 ve methylbenzethonium %12 içeren merhem (Leishcutan®) L. majorlü 67 olgunun %87'sinde etkili bulunmuştur. Lokal ağrı, deri irritasyonu ve ödem gibi istenmeyen reaksiyonlar gelişebilir (49).…”

Section: Resim 4 Yaymada Makrofajlar Içinde Ve Dışında Amastigotlar unclassified

Cutaneous Leishmaniasis

Harman¹

2015

tdd

View full text Add to dashboard Cite

Leishmaniasis, leishmania türlerinin neden olduğu ve enfekte dişi tatarcıkların ısırmasıyla insanlara bulaşan bir dizi hastalığı tanımlamaktadır. Hastalığın kutanöz, mukokutanöz ve visseral olmak üzere üç ana formu bulunmaktadır. Dünya Sağlık Örgütü verilerine göre, tüm dünyada toplam 98 ülkede yaklaşık 12 milyon insan leishmaniasise yakalanmış durumda olup, 350 milyon kişinin ise risk altında yaşadığı bildirilmektedir. Her yıl bu rakamlara 2 milyon yeni olgunun katıldığı, bu olguların yaklaşık dörtte üçünün kutanöz leishmaniasis (KL) olduğu tahmin edilmektedir. Bilimsel ve medikal topluluklar tarafından 20. yüzyılda ve 21. yüzyılın başlarında leishmaniasis hakkında çok şey öğrenilmesine rağmen hastalığın kontrolü ve idaresi hala zordur. Bu makalede hastalığın en yaygın formu olan KL'nin, özellikle epidemiyolojisi ve tedavisine odaklanılmaktadır. Anahtar kelimeler: Leishmaniasis, kutanöz, epidemiyoloji, etiyopatogenez, tedavi, korunma Mehmet Harman Kutanöz Leishmaniasis Cutaneous Leishmaniasis Öz AbstractLeishmaniasis is used to describe a spectrum of diseases caused by the parasitic protozoa leishmania spp. and transmitted by infected female sandflies. There are three main forms of the disease; cutaneous, mucocutaneous, and visceral. According to the World Health Organization, almost 12 million people from 98 countries worldwide are currently infected with leishmaniasis, while 350 million people are at risk. It was reported that 2 million new cases are diagnosed every year, with three-fourth are cutaneous leishmaniasis (CL) cases. The scientific and medical communities have learnt a lot about CL during the 20 th and early 21 st centuries. However, the management and control of the disease remains a difficult task. This article was focused on the most common form of the disease, cutaneous leishmaniasis, and especially its epidemiological aspects and treatment.

show abstract

Topical treatment of cutaneous leishmaniasis.

Abstract: CL. An in vitro model for testing the effect of anti-leishmanial drugs of possible use in topical treatment.

Cited by 32 publications

References 3 publications

Randomized, controlled, double-blind trial of topical treatment of cutaneous leishmaniasis with paromomycin plus methylbenzethonium chloride ointment in Guatemala.

Randomized, controlled, double-blind trial of topical treatment of cutaneous leishmaniasis with paromomycin plus methylbenzethonium chloride ointment in Guatemala.

Differential Effects of Paromomycin on Ribosomes of Leishmania mexicana and Mammalian Cells

Cutaneous Leishmaniasis

Contact Info

Product

Resources

About